Ruggeri, M., Basile, M., Armuzzi, A. and Cicchetti, A. 2017. Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn’s disease: Analisi Organizzativa e di Budget Dell’introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn. Global and Regional Health Technology Assessment. 4, 1 (Aug. 2017), 88–99. DOI:https://doi.org/10.33393/grhta.2017.382.